Research programme: serotonin 6 receptor antagonists - Suven Life Sciences

Drug Profile

Research programme: serotonin 6 receptor antagonists - Suven Life Sciences

Alternative Names: SUVN-501; SUVN-504; SUVN-507; SUVN-512; SUVN-623; SUVN-901; SUVN-976

Latest Information Update: 27 Dec 2016

Price : $50

At a glance

  • Originator Suven Life Sciences
  • Class Carbazoles; Indoles; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cognition disorders; Obesity; Parkinson's disease; Schizophrenia

Most Recent Events

  • 07 Dec 2016 Suven Life Sciences has patent protection for selective 5-HT6 compounds in India
  • 26 Sep 2016 Suven Life Sciences has patent protection for selective 5-HT6 compounds and H3 inverse agonist compounds in India and Japan
  • 05 Jan 2016 Suven Life Sciences has patent protection for chemical entities targeting serotonin receptors for the treatment of neurodegenerative disorders in Canada, Africa and South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top